Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$2.22 - $3.39 $114,108 - $174,246
-51,400 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$1.8 - $3.3 $92,520 - $169,620
51,400 New
51,400 $112,000
Q2 2018

Aug 14, 2018

SELL
$9.52 - $12.15 $259,543 - $331,245
-27,263 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$6.7 - $12.95 $77,552 - $149,896
-11,575 Reduced 29.8%
27,263 $287,000
Q4 2017

Feb 14, 2018

BUY
$5.07 - $7.92 $196,908 - $307,596
38,838
38,838 $249,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.